ATM and neoplasm: Given the role of ATM as an intermediate risk factor for breast, hematological, and pancreatic cancers and as marker of PARPi response, the classification of ATM variants is essential for appropriate diagnostic and therapeutic management, and has thus been routinely included in the tumor gene panel for NGS.